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Abstract
Objective—The use of psychotropic medications in Alzheimer’s disease (AD) has been
associated with both deleterious and potentially beneficial outcomes. We examined the
longitudinal association of psychotropic medication use with cognitive, functional, and
neuropsychiatric symptom (NPS) trajectories among community-ascertained incident AD cases
from the Cache County Dementia Progression Study.
Methods—A total of 230 participants were followed for a mean of 3.7 years. Persistency index
(PI) was calculated for all antidepressants, selective serotonin reuptake inhibitors (SSRIs),
antipsychotics (atypical and typical), and benzodiazepines as the proportion of observed time of
medication exposure. Mixed-effects models were used to examine the association between PI for
each medication class and Mini-Mental State Exam (MMSE), Clinical Dementia Rating Sum of
Boxes (CDR-Sum), and Neuropsychiatric Inventory – Total (NPI-Total) trajectories, controlling
for appropriate demographic and clinical covariates.
Results—At baseline, psychotropic medication use was associated with greater severity of
dementia and poorer medical status. Higher PI for all medication classes was associated with a
more rapid decline in MMSE. For antidepressant, SSRI, benzodiazepine, and typical antipsychotic
use, a higher PI was associated with a more rapid increase in CDR-Sum. For SSRIs,
antipsychotics, and typical antipsychotics, a higher PI was associated with more rapid increase in
NPI-Total.
Conclusions—Psychotropic medication use was associated with more rapid cognitive and
functional decline in AD, and not with improved NPS. Clinicians may tend to prescribe
psychotropic medications to AD patients at risk of poorer outcomes, but one cannot rule out the
possibility of poorer outcomes being caused by psychotropic medications.
Keywords
Alzheimer’s disease; antidepressants; antipsychotics; SSRI; cognition; psychosocial function;
neuropsychiatric symptoms; epidemiology; pharmacoepidemiology
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Neuropsychiatric symptoms (NPS) are prevalent in Alzheimer’s disease (AD) (Steinberg et
al., 2008), and psychotropic medications are widely used to treat them, with up to one-third
of patients with AD taking antidepressants or antipsychotics (Gruber-Baldini et al., 2007;
Kamble et al., 2009). These medications are widely used despite doubts as to their safety
and effectiveness (Sink et al., 2005; Drye et al., 2010; Rosenberg et al., 2010; Weintraub et
al., 2010). Previous studies of psychotropic medication in AD have identified potential
benefits and harms. The loss of serotonergic (Liu et al., 2008) and noradrenergic
(Weinshenker, 2008) innervation suggests that antidepressants that increase the availability
or enhance the action of these neurotransmitters might be beneficial in slowing disease
progression (Nelson et al., 2007; Lauterbach et al., 2010). There is evidence for
antidepressants improving several domains of NPS in dementia including depression
(DIADS-2 Rosenberg) and agitation (Pollock, 2002). Given that depression is associated
with cognitive deficits in older persons (Murphy and Alexopoulos, 2004), it is possible that
antidepressant treatment might improve cognition in depressed demented persons. There is
also evidence for antidepressants increasing hippocampal neurogenesis with similar
potential benefits (Malberg, 2004). Conversely, antipsychotic medication use has been
associated with increased mortality (Schneider et al., 2005; Wang et al., 2005; Simoni-
Wastila et al., 2009) and poorer cognition (CATIE-AD paper), antidepressant use with
increased risk of hip fracture (Ensrud et al., 2003), and use of all major classes of
psychotropic medications with increased risk of falls (Woolcott et al., 2009). Given this
mixture of possible beneficial and harmful effects of psychotropic medication use in AD,
and in the absence of long-term randomized controlled trials for efficacy and safety, it is
important to examine whether use of these medications is associated with differential
outcomes in population studies. Three prior studies have addressed this question. ElluI and
colleagues reported that use of antipsychotics and sedatives (including benzodiazepines) but
not antidepressants in 224 community-dwelling persons with AD was associated with more
than a two-fold increase in the risk of functional deterioration (Ellul et al., 2007). A similar
study found no effect of antipsychotic use on the rate of change of the Severe Impairment
Battery (Livingston et al., 2007). In a longitudinal study of 179 AD participants followed for
a mean of 4 years, sedative use (including benzodiazepines) was associated with a twofold
increase in mortality risk and antipsychotic use with a twofold increase in the risk of
functional deterioration, but antidepressant use was not associated with either outcome
(Lopez et al., 1999).
A limitation of these studies is that they enrolled participants with prevalent rather than
incident dementia. Additionally, two of the three studies had a follow-up duration of 12
months or less, and none evaluated the association of medication use with change in NPS.
We, therefore, sought to examine the association of psychotropic medication use with
cognitive, functional, and NPS trajectories in a longitudinal population-based study of
incident AD participants enrolled in the Cache County Dementia Progression Study [DPS]
(Tschanz et al., 2011). We hypothesized that greater exposure to antipsychotic and
benzodiazepine use would be associated with more rapid decline in cognition and function,
and that antidepressant use would be associated with improvement in NPS (i.e. fewer
symptoms) and cognition.
Methods
Participants and dementia diagnosis
The DPS originated from the longitudinal, population-based Cache County Study on
Memory in Aging (CCSMA), which examined the prevalence, incidence, and risk factors of
dementia in a US county recognized for its residents’ longevity. In its first wave, the
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CCSMA enrolled 90% of 5677 county residents aged 65 years or older. Three triennial
incidence waves were subsequently completed, and incident cases were referred for
prospective follow-up by the DPS. The interval between follow-up visits varied from 6 to 18
months.
Methods of identification and diagnosis of Cache County residents with dementia have been
described (Tschanz et al., 2011). These methods resulted in preliminary diagnoses of
dementia according to DSM-III-R criteria. Dementia severity was rated on the Clinical
Dementia Rating (CDR) (Morris, 1993) and health status according to the General Medical
Health Rating (GMHR) (Lyketsos et al., 1999). A consensus panel of experts consisting of
neurologists, geropsychiatrists, neuropsychologists, and a cognitive neuroscientist then
reviewed all available clinical information and (when available) neuropathologic data,
assigning diagnoses of Possible or Probable AD according to NINCDS-ADRDA criteria
(McKhann et al., 1984) and estimating age of dementia onset. Study procedures were
approved by institutional review boards at Utah State, Duke, and the Johns Hopkins
Universities.
Measures of dementia progression
Mini-Mental State Exam (MMSE) (Folstein et al., 1975)—The MMSE is a global
measure of cognition used widely in AD research. As previously reported (Mielke et al.,
2007; Tschanz et al., 2011), an adjusted MMSE score was calculated by discarding items
missed because of sensory/motor impairment (e.g. severe vision or hearing loss, motor
weakness, tremor), calculating the percent correct of the remaining items, and rescaling the
final score on a 30-point scale.
Clinical Dementia Rating (Morris, 1993)—The CDR is a semi-structured interview to
assess dementia severity in six functional domains and has excellent reliability and validity
(Morris et al., 1997; Morris, 1997). The sum of the six domain scores (CDR-Sum) was
chosen here in preference to the composite CDR score because of its greater range and
sensitivity to change in mild cognitive impairment and AD (Pavlik et al., 2006).
Neuropsychiatric inventory-Clinician Rating (NPI-10) (Cummings et al., 1994)
—The NPI assesses type and severity of behavioral disturbances in dementia. NPI-10
evaluates 10 domains of NPS and records the frequency and severity for each domain. The
total score for each domain is calculated as the product of frequency★severity for that
domain, and NPI-Total is calculated as the sum of frequency★severity for all 10 domains.
The NPI has been widely used for quantifying neuropsychiatric symptoms in AD in
observational studies (Palmer et al., 2010) and in recent clinical trials (Porsteinsson et al.,
2008). Severity ratings for delusions, hallucinations, or agitation/aggression allowed the
rater to consider the use of PRN medications to control the behaviors to indicate “marked”
severity, similar to methods used in recent AD trials (Rosenberg et al., 2010).
Medication ascertainment and calculation of persistency index
Ascertainment of medication use relied on visual inspection of all available medication vials
at each follow-up (Zandi et al., 2002). When the participants were institutionalized, this
information was obtained from nursing home records. We classified current medication use
as regular if a medication from a particular psychotropic class was used ≥4 times per week.
Psychotropic medication classes were categorized and examined using the following classes:
all antidepressants, as well as a subset of these classified as selective serotonin reuptake
inhibitors (fluoxetine, sertraline, paroxetine, citalopram, fluvoxamine); all antipsychotics, as
well as a subset of these classed as atypical agents (olanzapine, risperidone, quetiapine,
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ziprasidone, and aripiprazole) and typical agents (all other antipsychotics); and
benzodiazepines.
Given the wide variety of possible patterns of medication exposure, we sought a summary
measure to quantify medication exposure. The Persistency Index (PI) (Rountree et al., 2009)
represents years of drug use divided by years of observation following AD diagnosis. It can,
therefore, range from 0 to 1, the latter indicating that the person has been taking a
medication from a psychotropic drug class over the entire study duration. Similarly, a PI of
0.5 indicates that the person was taking it over only half the study duration. Medication use
could be at any visit, and patients could have a PI >0 even if not taking medication at
baseline, so long as they were taking medication at least one follow-up visit. As we did not
have information on medication use between visits, if a person was taking a medication at
consecutive visits, we assumed s/he was taking it over the whole time-period between these
visits. If an individual was taking the medication at one visit but not at the next consecutive
visit, we estimated the time of drug use was half the time between visits. A PI was
calculated separately for each psychotropic medication class.
Statistical analyses
Group differences in baseline demographic and health-related characteristics were examined
using Fisher’s exact test for categorical variables and t-tests or analysis of variance with
post-hoc t-tests for continuous variables. For descriptive purposes, the PI was subdivided
into three categories: PI = 0 (no use), 0.01 <PI ≤ 0.5 (use half the time or less), PI ≥ 0.5 (use
more than half the time). For the regression analyses described below, PI was treated as a
continuous variable.
To model effects of PI on dementia progression, we examined average change in MMSE,
CDR-Sum, and NPI-Total from the visit at which dementia was first diagnosed, using linear
mixed effects models, treating subject-specific intercepts and linear change with time as
random effects. Because our analysis revealed significant non-linear time effects for both the
MMSE and CDR-Sum, and as we have carried out before in similar analyses (Tschanz et al.,
2011), we included a quadratic term (time2) and appropriate time2 terms in all examined
interactions. The following covariates were included in all models, based on the literature
and previous analyses with this dataset: baseline age, sex, education, estimated duration of
dementia prior to baseline visit, GMHR, and presence of one or two APOE ε4 alleles.
Additionally, models with MMSE and CDR-Sum as outcomes included baseline NPI-Total
as a covariate to account for the possibility that persons with higher NPI scores would be
more likely to be prescribed psychotropic medications. Education, sex, and APOE genotype
were determined at Wave 1 of the CCSMA. APOE genotype was determined from buccal
DNA using a standard protocol (Breitner et al., 1999). P <0.05 was used as the threshold for
statistical significance. All analyses were conducted using STATA Version 11.0 (StataCorp,
College Station, TX, USA).
Results
Demographics and clinical variables (Table 1)
A total of 335 participants were diagnosed with incident AD and enrolled in DPS, of whom
230 had at least one follow-up visit. The participants lacking follow-up were older, had
lower MMSE, higher CDR-Sum, and were less likely to be taking acetylcholinesterase
inhibitors. The median number of follow-up visits was one and the maximum 12, with mean
[SD] duration of follow-up 3.7[2.49] years and range 0.70–12.3 years. On average, the
participants were in their mid-80s, had one year of college, were more likely to be female,
and were diagnosed within 2 years of estimated AD onset.
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The PIs for each medication class are presented in Table 2. The prevalence of all-type
antidepressant use and of SSRI use was quite high, with 47.8% of participants taking an
antidepressant at some point during the study, 90% of which was SSRI use. The majority of
PIs for antidepressants and SSRIs were ≥0.5. We observed a lower prevalence of
antipsychotic use (29%) divided about equally between atypical and typical antipsychotics,
and with the majority of PIs being calculated as ≤0.5. About a quarter of the participants had
used benzodiazepines, with the majority of PIs being ≤0.5.
Most participants who took psychotropic medications were taking medications from more
than one psychotropic class. Among 82 participants taking an antidepressant at baseline,
only six (7%) did not take any other medication from another psychotropic class throughout
the study. Among 18 participants taking an antipsychotic at baseline, 14 (78%) were also
taking an antidepressant and seven (39%) a benzodiazepine; all participants also took at least
one medication from another psychotropic class throughout the study. Among 24
participants taking a benzodiazepine at baseline, 15 (63%) were also taking an
antidepressant and seven (29%) an antipsychotic; all participants also took at least one
medication from another psychotropic class throughout the study. Six participants (2.6% of
total) were taking an antidepressant, antipsychotic, and benzodiazepine at baseline.
There were specific baseline demographic and clinical variables associated with PI.
Comparing participants with PI >0.5 (“persistent” use) versus those with PI = 0 (no use),
persistent antidepressant use was associated with longer estimated duration of dementia
prior to diagnosis (mean[SD] 2[1.4] vs 1.5[1.2]) years, F1,2 = 3.23, p = 0.042), female
gender (81.2% vs 50.8%, p <0.001, Fisher’s exact test), higher CDR-Sum (6.5 [3.1] vs 4.9
[2.5], F1,2 = 6.72, p = 0.002), higher NPI total (6.5[9.7] vs 2.9[5.7], F1,2 = 6.14, p = 0.003),
and lower GMHR (2.6[0.6] vs 2.9[0.6], F1,2 = 8.3, p = 0.003). Persistent SSRI use was
associated with younger age (83.2[6] vs 86.2[6.2] years, F1,2 = 5.00, p = 0.008), female
gender (78% vs 54.5%, p = 0.006, Fisher’s exact test), higher CDR-Sum (6.6[3.1] vs
4.8[2.5], F1,2 = 9.54, p < 0.000), higher NPI total (6.3[9.3] vs 3.2[6.5], F1,2 = 4.24, p =
0.016), and lower GMHR (2.6[0.6] vs 2.9[0.6], F1,2 = 4.99, p = 0.008). Persistent
antipsychotic use was associated with female gender (93.3% vs 58.3%, p = 0.010, Fisher’s
exact test), presence of at least one APOE ε4 allele (73.3% vs 40.7%, p = 0.026 Fisher’s
exact test), and higher CDR-Sum (7.4[3.7] vs 6.4[3.6], F1,2 = 1.35, p = 0.001). Persistent
atypical antipsychotic use was associated with higher CDR-Sum (9.1[4.4] vs 6.2[2.3], F1,2 =
7.19, p = 0.001). Persistent use of typical antipsychotics and benzodiazepines was not
significantly associated with any clinical variables examined.
Associations of PI with trajectory of MMSE, CDR-sum, and NPI-total
The associations between PI and each individual outcome were examined with linear mixed-
effects models, controlling for baseline age, gender, education, estimated duration of
dementia prior to baseline visit, the presence of at least one APOE4 allele, and GMHR
(Table 3). For all medication classes and for co-use of antipsychotics and antidepressants, a
higher PI was associated with a more rapid decline on the MMSE (graphically illustrated in
Figure 1 for antipsychotic use). Similarly, higher PIs for anti-depressant, SSRI,
benzodiazepine, and typical antipsychotics were associated with a more rapid increase in
CDR-Sum. None of the PIs for any medication class were associated with a decrease in NPI-
Total, and higher PIs for SSRIs, antipsychotics, and typical antipsychotics were associated
with more rapid increase in NPI-Total. In all models, the coefficient for PI*time2 was
opposite in sign to that for PI*time, indicating that the rate of change decreased over time.
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In this population-based sample of incident AD dementia, we observed that longer duration
of exposure to all major classes of psychotropic medications (quantified by PI) was
associated with a more rapid rate of decline in general cognition (MMSE), and several
classes of medicines were associated with more rapid increase in dementia severity (CDR-
Sum) and NPS (NPI). These results strengthen prior reported associations of poorer
outcomes with exposure to antipsychotics and benzodiazepines and extend these
observations to antidepressants, including SSRIs, and to both typical and atypical
antipsychotics. The association of greater benzodiazepine PI with more rapid cognitive and
functional decline adds to a substantial literature implicating benzodiazepines with adverse
outcomes in AD and indeed in older persons in general. Figure 1 depicts a consistent result
of our modeling that the rate of decline itself declines over time, that is, the rates of change
in outcomes tend to decelerate over time.
All classes of psychotropic medication were widely used over the study duration (ranging
from 15 to 48%) with close to half of the participants using antidepressants and one-quarter
using antipsychotics and benzodiazepines over the course of the study. The duration of
exposure differed by medication classes, with antipsychotics and benzodiazepines generally
being taken less than half the time and antidepressants (mostly SSRIs) more than half the
time. The data at enrollment provide strong evidence that psychotropic medications were
being prescribed to participants who had greater symptom severity (Lopez et al., 2010;
Tschanz et al., 2011). Greater baseline functional impairment (CDR-Sum) was associated
with more use of all medication classes except typical antipsychotics. Antidepressants,
including SSRIs, were used more by those with greater initial severity of NPS as evidenced
by NPI-Total. Female gender and younger age also were associated with greater PI for all
classes except atypical antipsychotics and benzodiazepines. Polypharmacy of psychotropic
medications was common. The strength of the associations may diminish over long periods
of time (10 years) as illustrated in Figure 1, but it is important to note that these are models
whose validity over long periods of time should be interpreted with caution.
These results support two plausible explanations: Psychotropic medications are prescribed to
AD participants who were already at risk of poorer outcomes, and their use is associated
with more rapid decline. These data cannot, however, determine whether the more rapid
decline is causally related to the medications or whether an underlying feature of the
pathobiology of a specific aspect of the disease causes more severe dementia, more NPS,
and worse medical health and is, therefore, the cause of the more rapid decline. Psychotropic
medication exposure was also associated with younger age, which has been reported to be a
risk factor for more rapid cognitive and functional decline in AD (Lopez et al., 2010).
These results do not support a long term benefit from the use of any class of psychotropic
drug, but it is possible that decline would have been more rapid had these drugs not been
used. A recent randomized controlled trial of antipsychotics for psychosis in AD lessens
concern that participants’ use of the treatments was a reflection of their need for such
medicines (e.g., because of greater severity of illness at enrollment), but it did not
demonstrate long-term benefit either (Sultzer et al., 2008). Taken together, these results
support current practice of attempting to use non-pharmacologic treatments, first unless the
risk of harm or distress is high, and of recommendations that trials off drug are indicated in
most cases.
Strengths of this study include its examination of persons with incident AD who were
ascertained from a population-based sample. Most prior reports have relied on clinical or
convenience samples. Second, the diagnoses of AD were established by an interdisciplinary
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geropsychiatric team that had the benefit of multiple forms of information, including
longitudinal observations in most instances and neuropathologic confirmation in a sample.
Third, the mean duration of follow-up averaged 3.7 years, longer than any clinical trial and
most observational studies. Fourth, ascertainment of medication use was by direct
observation on home visits rather than self-report or pharmacy records, a method that is
likely to maximize reliability of medicine use data.
The primary limitation of the study is its observational design that cannot exclude
confounding by indication, that is, that the observed association is a reflection of some other
shared attribute such as symptom or illness severity. Conversely, it is also possible that
participants with improvement in NPI may have discontinued these medications, biasing the
NPI outcomes toward a negative association with medication use. Further limitations
include the following: (i) modifications to the wording of specific NPI domains may have
served to bias NPI scores upward; (ii) the NPI total is the sum of 10 domains and may not
have sufficient range or sensitivity to detect change in one domain from a single drug class;
(iii) we lacked information about the duration of psychotropic medication use prior to
baseline, which may have influenced the outcomes; (iv) the PI is a calculated variable that
summarizes duration of medication exposure, but in summarizing does not incorporate the
details of when medications were stopped and started. There are several types of
associations that cannot be captured with such a summary variable, such as delayed or
transient effects of medication exposure. Additionally, “confound by indication” can include
the possibility that medication discontinuation was associated with improvement in
symptoms (particularly NPI), which would tend to bias the associations in the directions we
observed; and (v) although the associations present a relatively consistent pattern, certain
associations (particularly associations of medication use with NPI trajectory) would not be
significant after adjustment for multiple comparisons. Finally, the study would inevitably
have benefited from a larger sample size, increased duration of follow-up, and use of a more
elaborate summary measure of cognition than the MMSE.
We suggest that the most likely explanation of our findings is that psychotropic medications
are preferentially prescribed to AD patients whose clinical characteristics are associated with
poorer prognosis including neuropsychiatric symptoms and problem behaviors. We base this
suggestion on the observation that virtually all classes of psychotropic medications were
associated with poorer outcomes, suggesting that this is an effect of prescribing practices
rather than specific effects of individual medications. However, given the prevalence of
polypharmacy, this study has limited power to distinguish effects of individual medications.
Given these caveats, we cannot rule out the possibility that psychotropic medications have a
deleterious effect on the clinical course of AD. To some extent this sort of question can be
resolved by larger observational data sets with more elaborate data collection routines and
longer follow-up intervals. More likely, however, the ultimate answer to these questions is
better left to randomized trials.
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Mixed effect models of MMSE versus time, stratified by PI. The results of mixed-effect
modeling of MMSE versus time stratified by antipsychotic persistency index (PI). These
models included two-way interactions between PI and time/time2 and controlled for baseline
age, gender, education, estimated duration of dementia prior to baseline visit, the presence of
at least one ApoE4 allele, GMHR baseline use of acetylcholinesterase inhibitors and
memantine, and baseline NPI-Q Total. The curves represent bestfit models to observed data
and are of different durations due to differing duration of available follow-up data.
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PI = 0 0 <PI ≤ 0.5 PI >0.5 PI >0
Antidepressants 120(52.2) 41(17.8) 69(30) 110 (47.8)
SSRIs 134(58.3) 37(16.1) 59(25.7) 96 (42.8)
Antipsychotics 163(70.9) 52(22.6) 15(6.5) 67 (29.1)
Atypical antipsychotics 195(84.8) 27(11.7) 8(3.5) 35 (15.2)
Typical antipsychotics 182(79.1) 42(18.3) 6(2.6) 48 (20.9)
Benzodiazepines 172(74.8) 42(18.3) 16(7) 58 (25.3)
PIs are presented for each medication class for the 230 participants who had at least one follow-up visit after baseline in the DPS. The PI was
calculated as the ratio of the estimated time participant taking medication to the total duration of follow-up as defined in the Methods. PI was
categorized as PI = 0, 0 <PI <≤0.5, and PI >0.5, as well as PI >0 (i.e., any use of medication).
PI, persistency index; SSRIs, selective serotonin reuptake inhibitors; DPS, dementia progression study.
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